Twist Bioscience Corporation at Jefferies Global Healthcare Conference in London - TWIST BIOSCIENCE CORP
Explicit Guidance:
- FY2027 (ending September) revenue guidance of $550–$560 million.
- AI-driven discovery revenue guidance of $100 million for FY2027, with potential for upside beyond this amount if capacity constraints are resolved.
- Capex investment of $150 million over the next two years: $75 million in FY2026 and $75 million in FY2027.
- Targeting double-digit percentage growth in the broader company revenue (approx. 20% compound), while AI discovery segment expects triple-digit growth.
- Addressed EBITDA break-even for the first time in the most recent quarter.
Business-Segment Outlook:
- AI Drug Discovery: Projected to grow from $59M (FY2026) to at least $100M (FY2027). Growth trajectory moves from lumpy pilot orders ($10k–$100k) to recurring, high-volume production revenue as customers advance through model-building phases.
- NGS & MRD: Expecting "huge driver of growth" in FY2027 and beyond for Minimal Residual Disease (MRD) as market shifts to high-sensitivity testing requiring thousands of probes (up from 16), leveraging Twist's probe synthesis scale.
- New Product Introduction: Expanding DNA "flavors" to support a Total Addressable Market (TAM) growth from $7B (current) to a line-of-sight $13B.
- Capacity Expansion: Scaling from 10 to 16 "riders" (synthesis units) in coming quarters, plus automation in GeneLab 1 & 2 and increased characterization equipment (upgrading from 1–2 to 5–10 units).
Market and Competitive Outlook:
- Cell-Free vs. Cell-Based: Anticipating increased market adoption of cell-free synthesis for AI discovery due to its speed advantage (weeks faster than cell-based), despite lower material yield.
- Product Differentiation: Uniquely positioned as the only supplier at scale for pooled DNA discovery (reducing cost per data point) and cell-free synthesis for both single and multi-domain proteins, whereas competitors primarily serve single-domain.
- Pricing Strategy: Aiming to shift market standard from "arrayed discovery" ($150–$600 per data point) to "pooled discovery" to significantly lower costs per data point while increasing total volume.
- Academic/Government: Expecting upside if this market rebounds; currently taking meaningful share in a tough environment due to value proposition (quality, speed, price).
Macro / Industry Outlook:
- Economic Sensitivity: Business model viewed as resilient; unique value proposition becomes "even stronger" in a tough market where customers actively seek cost-efficient switching suppliers.
- AI Integration: AI-driven drug discovery demand is accelerating, with a "huge sense of urgency" in the field driving rapid scaling of wet-lab services.
- Regulatory/Market Structure: No specific regulatory changes mentioned, but anticipated market evolution toward high-sensitivity MRD and multi-domain protein therapeutics.
Strategic Initiatives:
- Capacity Buildout: Deployment of $75M Capex in FY2027 to add synthesis capacity, specifically targeting AI discovery demand; focus on "copy-pasting" existing operating instruments to minimize technical risk.
- Market Expansion: Launch of cell-free services to the entire market two weeks prior to the call; expansion of pooled DNA discovery offerings.
- Software Integration: Investing in software integration as the primary rate-limiting step to manage increased capacity and menu breadth.
Risks and Headwinds to Outlook:
- Capacity Constraints: The primary limiting factor for AI revenue realization beyond the $100M guide; long lead times for adding "riders" and characterization equipment.
- Software Bottlenecks: Software integration identified as the "rate-limiting step" for scaling operations.
- Execution Risk: "Cake eating" discipline required to manage rapid scaling without over-investing in capacity ahead of demand.
- Market Rebound Dependency: Upside in Academic/Government is explicitly not built into guidance and relies on a broader market recovery.
Management Tone on the Future:
- Confidence: High confidence in the "compounding" nature of AI customer cohorts (pilot -> model building -> production) and the ability to predict demand a year in advance.
- Tech Risk Assessment: Described as "minimal" for capacity scaling, characterized by low risk due to replication of proven technology.
- Growth Trajectory: Management expresses excitement about the "huge opportunity" and "accelerating rate of expansion," viewing the current quarter as a "milestone" toward best-in-class financial performance.
Miscellaneous:
- Customer Cohort Evolution: Early AI cohort (e.g., top-5 pharma, AI-native companies) follows a predictable 3-phase cycle; revenue predictability increases in Phase 3 (production).
- Modality Upgrade: Expectation that current AI customers using single-domain proteins (VHH) will graduate to multi-domain (IgG) and multi-specific IgGs, requiring significantly more data points.
- Competitive Landscape: Noting limited number of "Mag 7" AI companies and few pharma fully converted to AI, implying significant room for conversion among remaining pharma.
- Company
- TWIST BIOSCIENCE CORP
- Keywords
- TWIST BIOSCIENCE CORP